In continuing our series 'Live from @BIOconvention 2017' Health Innovation Media co-host Douglas Goldstein (@eFuturist) catches up with Jeff Galvan, CEO of American Gene Technologies™ (AGT) a Maryland based company:
'...developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, Phenylketonuria (PKU) and Hepatocellular carcinoma (liver cancer, or HCC).'
In 2016 American Gene Technologies™ had a successful pre-IND meeting with the FDA for AGT103, an HIV functional cure. This meeting launched the IND development process and the planned clinical trial in 2017. AGT filed patents for unique drug candidates that demonstrated high efficacy against the HIV virus in preliminary tests. AGT launched it Series D funding round to support the HIV clinical trials.
Produced by Gregg A. Masters, MPH (@2healthguru) for Health Innovation Media.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register